Introduction {#s5}
============

The risk of hypoglycemia (glucose \<70 mg/dL) with diabetes treatment is well recognized, and its prevention is considered a "critical component of diabetes management" ([@B1]). Episodes of severe hypoglycemia (SH), defined in this study as requiring hospitalization or emergency department visit in patients with type 2 diabetes, can be identified through structured electronic medical record (EMR) or administrative data ([@B2],[@B3]). However, nonsevere hypoglycemia (NSH), not requiring assistance for recovery ([@B1]), is often reported by patients during outpatient visits and captured only if an EMR hypoglycemia diagnosis code is entered. Natural language processing (NLP) combines computer science and linguistics methods ([@B4]) and can be used to extract nonstructured EMR text data. The improvement of EMR hypoglycemia detection using NLP had been previously reported ([@B5]). We aimed to describe capture of NSH in patients with type 2 diabetes using both diagnosis codes and NLP and to create a predictive model for SH events.

Research Design and Methods {#s6}
===========================

We used a modified version of the algorithm used by Kho et al. ([@B6]) to identify patients in the Cleveland Clinic Health System with type 2 diabetes during 2005 to 2017. Hypoglycemia events were identified using ICD-9/ICD-10 codes ([Supplementary Appendix 1](https://doi.org/10.2337/figshare.12116709)); events not associated with hospitalization/emergency department visit were categorized as NSH. A randomly selected subset of patient records stratified by years was reviewed to confirm code identification of NSH. The study protocol was approved by the Insitutional Review Board at Cleveland Clinic (Cleveland, OH).

Using clinical progress notes, an NLP algorithm was developed. The cTAKES program ([@B7]) was used to break down sentences into phrases to identify hypoglycemia-related Unified Medical Language System concepts. Regular expressions were written to classify polarity (event or no event) of phrases by pattern matching. Using word embeddings, the remaining phrases were classified with additional pattern matching (see [Supplementary Appendix 2](https://doi.org/10.2337/figshare.12116709) for detailed descriptions). For each year, 100 events were randomly selected, with 2005 to 2006 combined given the lower number of notes. The phrases were reviewed by practicing clinicians and confirmed through record review of a subset of patients as representing true events. The weighted proportion of actual events in a set of 1,200 notes was used to define the positive predictive value.

We then limited our data set to include patients with at least one primary care or endocrinology department visit each year and created a Cox proportional hazards prediction model for SH (5 years' duration) using the following variables based upon our previous work ([@B2]): sex, race, median income ([@B8]), history of comorbidities (cardiovascular disease, congestive heart failure \[CHF\], depression, other psychiatric disorders, dementia, cognitive impairment, chronic kidney disease \[CKD\], and alcohol or substance abuse), and time-dependent varables including age, insurance type (Medicare, Medicaid, commercial, or other), glycosylated hemoglobin (HbA~1c~), BMI, and diabetes medications (insulin, sulfonylurea, glucagon-like peptide 1 receptor agonists \[GLP-1RAs\], sodium--glucose cotransporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors, metformin, and α-glucosidase inhibitors). We had previously identified NSH by ICD codes as a variable associated with SH but for this study added two variables: ever-history of NSH and history of NSH within the past 3 months detected by codes and NLP. We also included interaction variables for HbA~1c~, with insulin, and with sulfonylureas.

Results {#s7}
=======

The number of patients with type 2 diabetes in this data set increased from 12,706 in 2005 to 176,001 in 2017 (210,191 unique patients). A total of 1,177,590 progress notes were processed. Upon clinician chart review, 1,111 of 1,200 randomly selected events classified as NSH by NLP were confirmed (93% positive predictive value). From 2005 to 2017, 10,205 NSH events were captured by codes and 14,763 events by NLP, with overlap of only 5 events. Among 204,517 patients with no codes for NSH, evidence of NSH was found in 7,035 (3.4%) using NLP.

The chart review confirmed NSH episodes were often documented under general diabetes diagnosis categories. The incidence proportion of patients with SH by ICD codes increased from 0.3 to 1.7% and those with NSH increased from 0.4 to 1.3% from 2005 to 2017. When NLP was added, the incidence proportion of patients with NSH increased from 0.8% (2005) to 2.6% (2017).

There were 47,280 patients included to create the prediction model for SH ([Supplementary Appendix 3](https://doi.org/10.2337/figshare.12116709)). The models using NSH codes alone and codes plus NLP ([Table 1](#T1){ref-type="table"}) had C-statistics of 0.812 and 0.806, respectively. The codes plus NLP model showed increased risk for SH with NSH (ever-history of NSH: hazard ratio \[HR\] 4.44, *P* \< 0.001; and NSH in past 3 months: HR 1.65, *P* \< 0.001), black race (HR 1.81; *P* \< 0.001), Medicaid insurance (HR 1.35; *P* = 0.008), history of cardiovascular disease (HR 1.58; *P* \< 0.001), CHF (HR 2.35; *P* \< 0.001), depression (HR 1.28; *P* = 0.03), psychiatric disorders other than depression (HR 1.55; *P* \< 0.001), alcohol or substance abuse (HR 1.55; *P* = 0.04), and CKD (HR 1.86; *P* \< 0.001). The effect of insulin use on SH was greater at lower HbA~1c~ (HR of 3.32 when HbA~1c~ is 6% \[42 mmol/mol\]; HR of 2.04 when HbA~1c~ is 9% \[75 mmol/mol\]). There was decreased risk of SH with higher BMI (HR 0.69 when BMI was 30 kg/m^2^; HR 0.63 when BMI was 35 kg/m^2^) and decreased risk with metformin (HR 0.53; *P* \< 0.001) and GLP-1RA (HR 0.36; *P* \< 0.001). Sulfonylurea use had a mixed effect on the risk of SH (HR of 1.61 when HbA~1c~ was 6% \[42 mmol/mol\]; HR of 0.69 when HbA~1c~ was 9% \[75 mmol/mol\]). The effect of HbA~1c~ varied at the extremes. With a reference HbA~1c~ of 6% (42 mmol/mol), the HR for SH was 1.59 at an HbA~1c~ of 5% (31 mmol/mol), HR was 0.73 at an HbA~1c~ of 7% (53 mmol/mol), and HR was 1.39 when HbA~1c~ was 9% (75 mmol/mol). Of note, NSH within the past 3 months was only a significant predictor in the the model including NLP. Receiver operating characteristic curves comparing code-detected NSH, NLP-detected NSH, and code plus NLP--detected NSH models were similar ([Supplementary Appendix 4](https://doi.org/10.2337/figshare.12116709)), while Kaplan-Meier curves for probability of being free from SH showed lower probability for code-detected NLP ([Supplementary Appendix 5](https://doi.org/10.2337/figshare.12116709)).

###### 

**Prediction models for risk of SH according to method used for capturing NSH events: diagnosis codes only or diagnosis codes plus NLP**

  Variable                                                              NSH using diagnosis codes (C index = 0.812)   NSH using diagnosis codes plus NLP (C index = 0.806)                                        
  --------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------ --------- ----------- -------------- ---------
  History of NSH in past 3 months                                       1.116                                         0.805, 1.546                                           0.51      1.647       1.239, 2.189   \<0.001
  Ever-history of NSH                                                   8.872                                         7.464, 10.546                                          \<0.001   4.441       3.745, 5.268   \<0.001
  Age                                                                   1.004                                         0.996, 1.012                                           0.30      1.007       0.999, 1.015   0.08
  Sex, male                                                             0.906                                         0.78, 1.054                                            0.20      0.866       0.745, 1.007   0.06
  Race                                                                                                                                                                       \<0.001                              \<0.001
   White                                                                Reference                                                                                                      Reference                  
   Black                                                                1.827                                         1.527, 2.186                                                     1.813       1.515, 2.169   
   Other                                                                1.031                                         0.741, 1.435                                                     1.060       0.762, 1.475   
  Median income (per 1,000 U.S. dollars), based on patient's zip code   0.999                                         0.995, 1.003                                           0.57      0.999       0.996, 1.003   0.76
  Insurance                                                                                                                                                                  0.009                                0.008
   Medicare                                                             Reference                                                                                                      Reference                  
   Medicaid                                                             1.359                                         1.013, 1.822                                                     1.351       1.007, 1.813   
   Commercial                                                           0.846                                         0.676, 1.058                                                     0.846       0.676, 1.058   
   Other                                                                0.787                                         0.582, 1.065                                                     0.772       0.571, 1.045   
  HbA~1c~, %[§](#tblfn5){ref-type="table-fn"}                                                                                                                                \<0.001                              \<0.001
   5                                                                    1.483                                         1.200, 1.832                                                     1.593       1.289, 1.969   
   6                                                                    Reference                                                                                                      Reference                  
   7                                                                    0.770                                         0.650, 0.912                                                     0.725       0.611, 0.859   
   8                                                                    1.007                                         0.832, 1.219                                                     0.932       0.770, 1.129   
   9                                                                    1.502                                         1.207, 1.870                                                     1.385       1.113, 1.724   
  BMI, kg/m^2^[‖](#tblfn6){ref-type="table-fn"}                                                                                                                              \<0.001                              \<0.001
   25                                                                   Reference                                                                                                      Reference                  
   30                                                                   0.712                                         0.638, 0.795                                                     0.690       0.618, 0.770   
   35                                                                   0.644                                         0.569, 0.729                                                     0.630       0.557, 0.713   
  Cardiovascular disease                                                1.625                                         1.359, 1.944                                           \<0.001   1.579       1.321, 1.889   \<0.001
  CHF                                                                   2.261                                         1.821, 2.807                                           \<0.001   2.349       1.893, 2.916   \<0.001
  Depression                                                            1.264                                         1.005, 1.589                                           0.045     1.282       1.02, 1.611    0.03
  Other psychiatric disorders                                           1.486                                         1.253, 1.763                                           \<0.001   1.549       1.307, 1.835   \<0.001
  Dementia                                                              1.410                                         0.905, 2.195                                           0.13      1.367       0.88, 2.124    0.16
  Cognitive impairment                                                  1.000                                         0.633, 1.58                                            1.0       1.051       0.667, 1.655   0.83
  CKD                                                                   1.843                                         1.529, 2.222                                           \<0.001   1.858       1.54, 2.241    \<0.001
  Alcohol or substance abuse                                            1.458                                         0.96, 2.215                                            0.08      1.551       1.021, 2.354   0.04
  Insulin[§](#tblfn5){ref-type="table-fn"}                                                                                                                                   \<0.001                              \<0.001
   HbA~1c~ 5%                                                           3.108                                         1.976, 4.888                                                     2.637       1.675, 4.153   
   HbA~1c~ 6%                                                           3.797                                         3.063, 4.706                                                     3.323       2.671, 4.134   
   HbA~1c~ 7%                                                           4.238                                         3.388, 5.300                                                     3.794       3.024, 4.761   
   HbA~1c~ 8%                                                           3.297                                         2.638, 4.121                                                     2.921       2.330, 3.661   
   HbA~1c~ 9%                                                           2.344                                         1.846, 2.977                                                     2.037       1.600, 2.594   
  Sulfonylurea[§](#tblfn5){ref-type="table-fn"}                                                                                                                              \<0.001                              \<0.001
   HbA~1c~ 5%                                                           2.934                                         1.765, 4.878                                                     2.484       1.498, 4.120   
   HbA~1c~ 6%                                                           1.806                                         1.434, 2.273                                                     1.610       1.280, 2.026   
   HbA~1c~ 7%                                                           1.160                                         0.907, 1.483                                                     1.085       0.849, 1.386   
   HbA~1c~ 8%                                                           0.885                                         0.698, 1.123                                                     0.851       0.671, 1.079   
   HbA~1c~ 9%                                                           0.705                                         0.533, 0.932                                                     0.694       0.525, 0.917   
  GLP-1RA                                                               0.364                                         0.228, 0.581                                           \<0.001   0.361       0.227, 0.576   \<0.001
  DPP-4                                                                 0.924                                         0.723, 1.181                                           0.53      0.869       0.68, 1.112    0.26
  SGLT2i                                                                0.539                                         0.255, 1.142                                           0.11      0.576       0.272, 1.22    0.15
  Metformin                                                             0.551                                         0.465, 0.653                                           \<0.001   0.532       0.449, 0.63    \<0.001
  AGI                                                                   1.279                                         0.527, 3.105                                           0.59      1.373       0.566, 3.335   0.48

AGI, α-glucosidase inhibitor; DPP-4, dipeptidyl peptidase 4 inhibitor; SGLT2i, sodium--glucose cotransporter 2 inhibitor.

Adjusted for NSH based on diagnosis code.

Wald test. For HbA~1c~, BMI, insulin, and sulfonylurea, it tests the linearity of the variable, all interactions, and all nonlinear terms.

Adjusted for NSH based on diagnosis code and NLP.

The restricted cubic spline term was used. The knots are placed at 6%, 7%, and 8% of HbA~1c~.

The restricted cubic spline term was used. The knots are placed at 25, 30, and 35 kg/m^2^ of BMI.

Conclusions {#s8}
===========

Building upon previous work identifying SH in our health system, we found that applying NLP to progress notes improved NSH detection and that NSH is a significant predictor for SH. However, SH prediction using NSH diagnosis codes did not improve with adding NLP, possibly related to the strength of the other variables in contributing to the model and possible greater severity of coded NSH as the Kaplan-Meier curves suggest. There was little overlap between NSH events by codes plus NLP, suggesting that while NSH may be reported by patients, providers may not enter a hypoglycemia diagnosis code, highlighting the benefit of NLP.

While it is known that NSH may have significant adverse consequences ([@B9]), treatment deintensification is uncommon ([@B10],[@B11]). Identifying patients with increased risk for hypoglycemia ([@B12],[@B13]) and alerting providers may affect provider behavior to adjust treatment for at-risk patients ([@B13]). Our prediction model identifies demographic characteristics and comorbidities predicting increased SH risk. Modifiable predictors include history of NSH and sulfonylurea and insulin use predicting increased risk of SH at lower HbA~1c~ levels and metformin and GLP-1RAs predicting lower risk. The HbA~1c~ effect is of higher predicted risk overall at very low HbA~1c~ levels at which treatment deintensification may be relevant, but also at very high HbA~1c~, at which fluctuating blood sugars may increase SH risk and limit ability to attain a lower HbA~1c~.

While our data set is robust, we recognize these limitations: *1*) the EMR from one health system does not capture NSH or SH events outside of the system, and *2*) lack of diabetes duration information in EMR for prediction. Future work will focus on notifying providers at the point of care of captured NSH events to consider deintensification, medication adjustments to lower SH risk, or meal and activity timing, especially in patients with multiple comorbidities, to reduce risk of future SH.

This article contains supplementary material online at <https://doi.org/10.2337/figshare.12116709>.
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